Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.70 2.36% 30.30 30.00 30.60 30.30 29.60 29.60 403,739 08:42:35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.6 -1.2 - 47

Skinbiotherapeutics Share Discussion Threads

Showing 7551 to 7574 of 8575 messages
Chat Pages: Latest  307  306  305  304  303  302  301  300  299  298  297  296  Older
DateSubjectAuthorDiscuss
08/9/2020
10:19
While it would have been nice to see a sizeable spike in the share price after that RNS, it does have the feel of a positive, additional building block sliding into place IMO. That said, we will be in a position to judge his success, or otherwise, within six months or so.
lovewinshatelosses
08/9/2020
08:09
Accelerated product development is not negative! Avoiding product development pitfalls is not negative! Having contacts across the product development landscape is not negative! Having an open short can be painful.
trumpingtonsmythe
08/9/2020
07:56
Seems a good appointment to me. I would think given his background his first task will be to get the clinical studies for the psoriasis underway. As ceo at his last job this would seem to have be its main purpose.
gary hindsight
08/9/2020
07:40
Obv a cost in short term but would appear a price worth paying. Within reason.
m4rtinu
08/9/2020
07:40
What a short sighted comment that was best. If you do not invest for the future as a company, at the right time, you fail to grow. Great relevant experience and NHS network contacts which will help promote the positive aspects of the companies products going forward.
aquaesulis01
08/9/2020
06:54
Will increase cash burn only negative
best1467
08/9/2020
06:44
Dr Jonathan Sheffield has been Chief Executive Officer of the National Institute for Health Research, Clinical Research Network since 2010. The Clinical Research Network delivers Clinical research studies throughout the NHS in England covering primary, secondary and tertiary care. The University of Leeds and Guy's and St Thomas' NHS Foundation Trust host the Network's Coordinating Centre from offices based in Leeds, London, Liverpool and Newcastle. In 2016-17 the Network recruited over 666,000 patients into over 4000 studies across the NHS. Jonathan qualified as a doctor in 1981 and subsequently trained as a Histopathologist. In 1993 he was appointed as a Consultant Histopathologist at Yeovil district General Hospital. Subsequently Jonathan has held multiple senior medical management posts in the NHS at local, regional and a national level.Jonathan is highly regarded for his knowledge and expertise and is often called upon to speak at national events and international industry meetings. In his capacity as an NIHR spokesperson, he provides comment on research delivery throughout the NHS infrastructure. His long and detailed experience in the NHS allows him to balance contentious clinical priority issues with the need to advance medical knowledge through research.A passionate advocate for clinical research, Jonathan's ambition is to focus not only on traditional pharma and medical technology research but how digital tools can accelerate delivery of life-changing treatments whilst improving engagement with patients, researchers, Life Science industry and the wider NHS.hTTps://business.leeds.ac.uk/divisions-management/dir-record/academic-industry-profiles/998/dr-jonathan-sheffield
parob
08/9/2020
06:41
Or'CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes.'Is adding to the area where strength is needed, the tech is fine it's the development knowledge that's needed?
trumpingtonsmythe
08/9/2020
06:38
Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said: "Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months." So he knows nothing about the technology, but, likes the idea?! Woooooow the pied piper at it again?
rayrac
08/9/2020
06:32
He wouldn't join just any old start up and would want to be associated with a genuine up and coming technology.
deeppockets
08/9/2020
06:30
Excellent appt. Great wealth of medical knowledge and presumably contacts too.
m4rtinu
08/9/2020
06:26
Great addition to the team.Stuart Ashman, CEO of SkinBioTherapeutics, said:"Jonathan will bring to SkinBioTherapeutics broad clinical knowledge accumulated over his career. Having served as CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes."Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said:"Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months."
parob
03/9/2020
08:09
The 35k was mine. I sold 34.5k on 11th August at 24.72p and in the meantime had a 20% ride on AAU. Back with a few more shares but have taken out £1500 to pay for a couple of things around the house.
zedder
02/9/2020
10:43
Probably acquired via existing shareholders and not via the open market?
slartybartfaster
02/9/2020
10:34
While I enjoy the buzz (even the nonsense posts!) of these chat boards after a significant piece of news, I think you have the right idea shrewdmole. I had a struggle buying here a while ago after a positive update, but I am probably a little overweight here at the moment, so I am still thinking of sitting tight until we hopefully see the first of Stuart's share price targets before I take a small top slice. So, plenty of troops behind him, even if we are not in plain sight :)
lovewinshatelosses
02/9/2020
10:08
When we get news it will move quickly!
deeppockets
02/9/2020
09:55
Very true. Wise words.
madaboutmed
02/9/2020
09:06
dont mind mate its just a quiet place and id prefer to buy now when its quiet. sbtx has a habit of being hard to get once it gets busy.
shrewdmole
02/9/2020
08:09
Looks like you are a lone soldier fighting the fight on your own
gary hindsight
02/9/2020
07:47
Little top up for me whilst it’s quiet.
shrewdmole
01/9/2020
20:09
I cannot comment on SPSY as I am unfamiliar with them. Having just had a quick glance though, it seems that the ii only declared a few days ago, so it may still have a healthy bearing on them in the weeks/months ahead. I certainly cannot think of an occasion where a company has seen its share price plunge upon declaration of a new ii on the register. Ultimately, it will be revenue - and more still profit - that will guide the landscape and the sentiment of any stock, although as some stocks have shown, they can be darlings or runts in the eyes of the market for years, before they even get to this stage. Some of course never even do. The management here so far have delivered, so until they prove otherwise, I cannot help but feel that some of the more adventurous iis might be missing a trick here. Anyway, given the state of the global economy, this is but a tiny consideration in the wider scheme of things.
lovewinshatelosses
01/9/2020
17:16
An II has just taken 10% stake in SPSY with negligible effect on the share price.
pj 1
01/9/2020
12:57
Lol. The usual suspects have been trying to sell the head and shoulders BS for years. Fails every time. Invest for the long term. Balls to charts.
slartybartfaster
01/9/2020
12:07
No real concerns here either, although I would still love to see one or two new institutional buyers come onto the scene at some point, in the not too distant future. That would underpin the share price somewhat and encourage new PIs to invest as well I think. Nothing wrong with traders or trading, but I know many people who avoid shares without at least several IIs on the register. Anyway, looking forward to the next update and hopefully it will be one that gets us through resistance and what appears to be the current trading range.
lovewinshatelosses
Chat Pages: Latest  307  306  305  304  303  302  301  300  299  298  297  296  Older
ADVFN Advertorial
Your Recent History
LSE
SBTX
Skinbiothe..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210119 09:53:13